Abstract |
UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.
|
Authors | John R Pollard |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 9
Issue 1
Pg. 101-7
(Jan 2008)
ISSN: 1472-4472 [Print] England |
PMID | 18183537
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticonvulsants
- Pyrrolidinones
- Seletracetam
|
Topics |
- Animals
- Anticonvulsants
(chemical synthesis, pharmacology, therapeutic use)
- Epilepsy
(drug therapy)
- Humans
- Parkinson Disease
(drug therapy)
- Pyrrolidinones
(chemical synthesis, pharmacology, therapeutic use)
- Structure-Activity Relationship
|